NNNN Anbio Biotechnology

Price (delayed)

$9.9

Market cap

$1.42B

P/E Ratio

66

Dividend/share

N/A

EPS

$0.15

Enterprise value

$1.42B

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: 26
Relative Profitability: Rel. Profitability: 99

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a ...

Highlights
The company's net income has surged by 170% YoY
The EPS has soared by 150% YoY

Key stats

What are the main financial stats of NNNN

NNNN stock price

How has the Anbio Biotechnology stock price performed over time
Intraday
1.64%
1 week
4.32%
1 month
-35.08%
1 year
-80.08%
YTD
-67.08%
QTD
-27.79%

Financial performance

How have Anbio Biotechnology's revenue and profit performed over time
Revenue
$8.65M
Gross profit
$7.54M
Operating income
$5.77M
Net income
$6.4M
Gross margin
87.2%
Net margin
74.1%
The operating income has surged by 189% year-on-year
The operating margin has surged by 173% year-on-year
The company's net income has surged by 170% YoY
Anbio Biotechnology's net margin has soared by 156% YoY

Price vs fundamentals

How does NNNN's price correlate with its fundamentals

Growth

What is Anbio Biotechnology's growth rate over time

Valuation

What is Anbio Biotechnology stock price valuation
P/E
66
P/B
47.24
P/S
50
EV/EBIT
221.25
EV/EBITDA
221.25
EV/Sales
163.85
The EPS has soared by 150% YoY
NNNN's equity has soared by 75% year-on-year
Anbio Biotechnology's revenue has increased by 6% YoY

Efficiency

How efficient is Anbio Biotechnology business performance
The ROS has soared by 156% YoY
The ROA has soared by 90% YoY
Anbio Biotechnology's ROE has soared by 82% YoY
The return on invested capital has grown by 2.4% year-on-year

Dividends

What is NNNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NNNN.

Financial health

How did Anbio Biotechnology financials performed over time
The total liabilities has dropped by 95% year-on-year
Anbio Biotechnology's total assets has surged by 60% YoY
Anbio Biotechnology's debt is 100% less than its equity
NNNN's equity has soared by 75% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.